alisporivir + peginterferon alfa-2a + ribavirin

This drug is a **combination therapy of alisporivir, peginterferon alfa-2a, and ribavirin**. Alisporivir is an oral, host-targeting small molecule that inhibits the *peptidyl-prolyl isomerase activity of cyclophilin A*, a host protein essential for hepatitis C virus (HCV) replication, thus exerting pan-genotypic anti-HCV activity with a high barrier to viral resistance. Peginterferon alfa-2a is a pegylated recombinant interferon that exerts antiviral and immunomodulatory effects, while ribavirin is a broad-spectrum antiviral nucleoside analog that inhibits viral RNA synthesis. The combination has been investigated, especially for chronic **HCV genotype 1 infection** (including patients with prior non-response or relapse to peginterferon/ribavirin). Alisporivir, when added to peginterferon alfa-2a and ribavirin, increases sustained virological response rates (SVR) compared to peginterferon alfa-2a and ribavirin alone[1][5][3]. Side effects seen more frequently with the triple combination include anemia, thrombocytopenia, hyperbilirubinemia, and hypertension.